Cargando…

Complete response to dupilumab in a patient with chronic spontaneous urticaria who did not tolerate omalizumab

Detalles Bibliográficos
Autores principales:	Zhu, Changhua, Fok, Jie Shen, Lin, Lihang, Su, Huichun, Maurer, Marcus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9880337/ https://www.ncbi.nlm.nih.gov/pubmed/36712834 http://dx.doi.org/10.1016/j.jdcr.2022.12.009

Ejemplares similares

Case report: Severe chronic spontaneous urticaria successfully treated with omalizumab and dupilumab
por: Puxkandl, Viktoria, et al.
Publicado: (2023)

Case Report: Omalizumab for Chronic Spontaneous Urticaria in Pregnancy
por: Liao, Shuang-Lu, et al.
Publicado: (2021)

Use of biologics in chronic spontaneous urticaria – beyond omalizumab therapy?
por: Metz, Martin, et al.
Publicado: (2021)

Omalizumab treatment and outcomes in Chinese patients with chronic spontaneous urticaria, chronic inducible urticaria, or both
por: Chen, Yudi, et al.
Publicado: (2021)

Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status
por: Casale, Thomas B., et al.
Publicado: (2023)

OMALIZUMAB IN TREATMENT-RESISTANT CHRONIC SPONTANEOUS URTICARIA
por: Godse, Kiran V
Publicado: (2011)

Profile of omalizumab in the treatment of chronic spontaneous urticaria
por: Labrador-Horrillo, Moises, et al.
Publicado: (2015)

Omalizumab's efficacy and safety against chronic spontaneous urticaria
por: Özdemir, Öner
Publicado: (2023)

Omalizumab in chronic spontaneous urticaria (CSU): experience in three cases
por: Valle, Solange Oliveira Rodrigues, et al.
Publicado: (2015)

Omalizumab is effective in the treatment of difficult-to-treat chronic spontaneous urticaria
por: Forgie, Jennifer, et al.
Publicado: (2014)

Sex differences in the efficacy of omalizumab in the treatment of chronic spontaneous urticaria
por: Sirufo, Maria Maddalena, et al.
Publicado: (2022)

Omalizumab treatment for chronic spontaneous urticaria: data from Turkey
por: Kara, Rabia Oztas, et al.
Publicado: (2022)

Cost‐effectiveness of personalized omalizumab dosing for chronic spontaneous urticaria
por: Denman, Sarah, et al.
Publicado: (2022)

Omalizumab substantially improves dermatology‐related quality of life in patients with chronic spontaneous urticaria
por: Finlay, A.Y., et al.
Publicado: (2017)

Angioedema and prescribing of omalizumab for chronic urticaria in countries with limited financial resources
por: Popov, Todor A., et al.
Publicado: (2019)

Omalizumab Updosing in Chronic Spontaneous Urticaria: an Overview of Real-World Evidence
por: Metz, Martin, et al.
Publicado: (2020)

Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria Who Remain Symptomatic on H(1) Antihistamines: A Randomized, Placebo-Controlled Study
por: Saini, Sarbjit S, et al.
Publicado: (2015)

Expert consensus on the use of omalizumab in chronic urticaria in China()
por: Zhao, Zuotao, et al.
Publicado: (2021)

Position statement for the use of omalizumab in the management of chronic spontaneous urticaria in Indian patients
por: Godse, Kiran, et al.
Publicado: (2016)

Refractory Chronic Spontaneous Urticaria Treated With Omalizumab in an Adolescent With Common Variable Immunodeficiency
por: Comberiati, Pasquale, et al.
Publicado: (2019)

Cost Utility of Omalizumab Compared with Standard of Care for the Treatment of Chronic Spontaneous Urticaria
por: Graham, Jonathan, et al.
Publicado: (2016)

Improving of psychological status and inflammatory biomarkers during omalizumab for chronic spontaneous urticaria
por: Diluvio, Laura, et al.
Publicado: (2020)

Response of FcεRI‐bearing leucocytes to omalizumab in chronic spontaneous urticaria
por: Alizadeh Aghdam, Mehran, et al.
Publicado: (2020)

Exploring Machine Learning Techniques to Predict the Response to Omalizumab in Chronic Spontaneous Urticaria
por: Sardina, Davide Stefano, et al.
Publicado: (2021)

Omalizumab Reduces Unplanned Healthcare Interactions in Irish Patients With Chronic Spontaneous Urticaria
por: Ridge, Katie, et al.
Publicado: (2021)

The course of COVID-19 in patients with chronic spontaneous urticaria receiving omalizumab treatment
por: Atayik, E., et al.
Publicado: (2022)

Multicentric and Observational Study of Omalizumab for Chronic Spontaneous Urticaria in Real-Life in Colombia
por: García-Gómez, Elizabeth, et al.
Publicado: (2022)

Omalizumab for chronic urticaria in Latin America
por: Wilches, Paul, et al.
Publicado: (2016)

Urticaria and angioedema as possible reactions of omalizumab
por: Ozbagcivan, Ozlem, et al.
Publicado: (2018)

Urticaria and mimickers of urticaria
por: Fok, Jie Shen, et al.
Publicado: (2023)

Efficacy and safety of omalizumab in Chinese patients with anti‐histamine refractory chronic spontaneous urticaria
por: Yuan, Weiru, et al.
Publicado: (2022)

Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin
por: Metz, Martin, et al.
Publicado: (2017)

Omalizumab on Chronic Spontaneous Urticaria and Chronic Inducible Urticaria: A Real-World Study of Efficacy and Predictors of Treatment Outcome
por: Jeong, Soo Hyun, et al.
Publicado: (2022)

A Long Term Case Series Study of the Effect of Omalizumab on Chronic Spontaneous Urticaria
por: Lefévre, Anna Cecilie, et al.
Publicado: (2013)

Case Report: Refractory Chronic Spontaneous Urticaria Treated With Omalizumab in an Adolescent With Crohn’s Disease
por: Barni, Simona, et al.
Publicado: (2021)

Successful treatment of intractable chronic spontaneous urticaria with omalizumab in a patient with ovarian cancer
por: Hayama, Koremasa, et al.
Publicado: (2021)

Omalizumab for the Treatment of Chronic Spontaneous Urticaria: Association Between Body Mass Index and Outcome
por: Russo, Irene, et al.
Publicado: (2022)

Changes of Gut Microbiome in Adolescent Patients with Chronic Spontaneous Urticaria After Omalizumab Treatment
por: Wang, Mei, et al.
Publicado: (2023)

PK/PD modeling to characterize placebo and treatment effect of omalizumab for chronic spontaneous urticaria
por: Oh, Elise, et al.
Publicado: (2023)

Total IgE as a Marker for Chronic Spontaneous Urticaria
por: Altrichter, Sabine, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3vjuf67ddc1daau9sinvsnrg0p